Endocrine therapy alone vs chemotherapy plus endocrine therapies for the treatment of elderly patients with endocrine-responsive and node positive breast cancer: A retrospective analysis of a multicenter study (Anatolian Society of Medical Oncology)

Simple item page
dc.contributor.authorInal A.
dc.contributor.authorAkman T.
dc.contributor.authorYaman S.
dc.contributor.authorDemir Ozturk S.
dc.contributor.authorGeredeli C.
dc.contributor.authorBilici M.
dc.contributor.authorInanc M.
dc.contributor.authorHarputoglu H.
dc.contributor.authorDemirci U.
dc.contributor.authorBalakan O.
dc.contributor.authorYesil Cinkir H.
dc.contributor.authorAlici S.
dc.contributor.authorUysal Sonniez O.
dc.contributor.authorGoksel G.
dc.contributor.authorGokoz Dogu G.
dc.contributor.authorUmit Unal O.
dc.contributor.authorTamozlu T.
dc.contributor.authorBuyukberber S.
dc.contributor.authorMelih Bomban C.
dc.contributor.authorIsikdogan A.
dc.date.accessioned2024-07-22T08:19:08Z
dc.date.available2024-07-22T08:19:08Z
dc.date.issued2013
dc.description.abstractPurpose: The extra benefit of adding chemotherapy to effective endocrine therapy (ET) has not been clearly or consistently identified in patients older than 70 years with estrogen receptor (ER) positive and node positive breast cancer. The aim of this study was to evaluate the efficacy of adjuvant ET vs chemotherapy plus endocrine therapies (Chemo/ET) in such patients. Methods: In this retrospective multicenter study 191 patients ≥ 70 years with operated hormone receptor positive breast cancer, who were administered adjuvant ET or Chemo/ET were assessed. Results: The median patient follow-up time was 29.0 months (range 1-252). Therefore disease free survival (DFS) and overall survival (OS) analysis was limited, due to the rather short median follow-up, and only 30-month cumulative percentages are reported herein. The 30-month DFS rates were 50.0% in the ET arm and 49.0% in the Chemo/ET arm (p=0.79). The 30-month OS rates were 86% in the ET arm and 96.0% in the Chemo/ET arm (p=0.08). Cox proportional hazard model showed that only surgery was independent prognostic factor for survival (p=0.047), while tumor size showed a strong trend for statistical significance (p=0.051). Conclusion: The addition of chemotherapy to endocrine therapy in older patients has no significant impact on DFS and OS.
dc.identifier.issn11070625
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/17547
dc.language.isoEnglish
dc.subjectAge Factors
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAntineoplastic Agents, Hormonal
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectAromatase Inhibitors
dc.subjectBreast Neoplasms
dc.subjectChemotherapy, Adjuvant
dc.subjectDisease-Free Survival
dc.subjectFemale
dc.subjectHumans
dc.subjectKaplan-Meier Estimate
dc.subjectLymphatic Metastasis
dc.subjectMastectomy
dc.subjectNeoplasms, Hormone-Dependent
dc.subjectProportional Hazards Models
dc.subjectReceptors, Estrogen
dc.subjectRetrospective Studies
dc.subjectRisk Factors
dc.subjectSelective Estrogen Receptor Modulators
dc.subjectTamoxifen
dc.subjectTime Factors
dc.subjectTreatment Outcome
dc.subjectTumor Markers, Biological
dc.subjectTurkey
dc.subjectcyclophosphamide
dc.subjectdocetaxel
dc.subjectdoxorubicin
dc.subjectepirubicin
dc.subjectfluorouracil
dc.subjectpaclitaxel
dc.subjecttamoxifen
dc.subjecttaxane derivative
dc.subjecttrastuzumab
dc.subjectarticle
dc.subjectbreast cancer
dc.subjectcancer adjuvant therapy
dc.subjectcancer chemotherapy
dc.subjectcancer hormone therapy
dc.subjectcancer prognosis
dc.subjectcancer size
dc.subjectcancer surgery
dc.subjectcancer survival
dc.subjectdisease free survival
dc.subjectdrug efficacy
dc.subjectfemale
dc.subjectfollow up
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmedical society
dc.subjectmonotherapy
dc.subjectmulticenter study
dc.subjectoverall survival
dc.subjectretrospective study
dc.titleEndocrine therapy alone vs chemotherapy plus endocrine therapies for the treatment of elderly patients with endocrine-responsive and node positive breast cancer: A retrospective analysis of a multicenter study (Anatolian Society of Medical Oncology)
dc.typeArticle

Files

Collections

Scopus Koleksiyonu